| Basics |
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.
|
| IPO Date: |
January 31, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.51B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.57 | 2.50%
|
| Avg Daily Range (30 D): |
$0.71 | 2.20%
|
| Avg Daily Range (90 D): |
$0.63 | 2.04%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.52M |
| Avg Daily Volume (30 D): |
1.09M |
| Avg Daily Volume (90 D): |
1.25M |
| Trade Size |
| Avg Trade Size (Sh.): |
67 |
| Avg Trade Size (Sh.) (30 D): |
50 |
| Avg Trade Size (Sh.) (90 D): |
59 |
| Institutional Trades |
| Total Inst.Trades: |
6,998 |
| Avg Inst. Trade: |
$2.82M |
| Avg Inst. Trade (30 D): |
$3.76M |
| Avg Inst. Trade (90 D): |
$3.52M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.51M |
| Avg Closing Trade (30 D): |
$6.47M |
| Avg Closing Trade (90 D): |
$6.57M |
| Avg Closing Volume: |
82.42K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-1.81
|
$-1.17
|
|
Diluted EPS
|
|
$-1.81
|
$-1.17
|
|
Revenue
|
$
|
$ 159.93M
|
$ 166.5M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -180.41M
|
$ -114.95M
|
|
Operating Income / Loss
|
$
|
$ -170.89M
|
$ -107.89M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 25.76M
|
$ 46.55M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jan 17, 2014:
15:47
|
|
|
|
